Last reviewed · How we verify
Sertraline HCl
Sertraline HCl is a Selective serotonin reuptake inhibitor (SSRI) Small molecule drug developed by Tri-Service General Hospital. It is currently FDA-approved for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder. Also known as: Zoloft.
Sertraline selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Sertraline HCl is a small molecule used to treat various conditions, including Major Depressive Disorder, Panic Disorder, and Myelodysplastic Syndromes, as well as sexual dysfunction associated with antidepressant use. It is a hydrochloride salt form of the medication Sertraline.
At a glance
| Generic name | Sertraline HCl |
|---|---|
| Also known as | Zoloft |
| Sponsor | Tri-Service General Hospital |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Sertraline is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and improving mood regulation. The mechanism is thought to underlie its efficacy in treating depression, anxiety disorders, and related conditions.
Approved indications
- Major depressive disorder
- Obsessive-compulsive disorder
- Panic disorder
- Post-traumatic stress disorder
- Social anxiety disorder
- Generalized anxiety disorder
- Premenstrual dysphoric disorder
Common side effects
- Nausea
- Diarrhea
- Headache
- Tremor
- Insomnia
- Sexual dysfunction
- Somnolence
- Dry mouth
Key clinical trials
- TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children (PHASE4)
- Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan (NA)
- ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression (PHASE2)
- Pattern Separation in Major Depressive Disorder (PHASE1)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Predicting SSRI Efficacy in Veterans With PTSD (PHASE4)
- Sertraline and the Risk of Serious Adverse Events
- Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sertraline HCl CI brief — competitive landscape report
- Sertraline HCl updates RSS · CI watch RSS
- Tri-Service General Hospital portfolio CI
Frequently asked questions about Sertraline HCl
What is Sertraline HCl?
How does Sertraline HCl work?
What is Sertraline HCl used for?
Who makes Sertraline HCl?
Is Sertraline HCl also known as anything else?
What drug class is Sertraline HCl in?
What development phase is Sertraline HCl in?
What are the side effects of Sertraline HCl?
What does Sertraline HCl target?
Related
- Drug class: All Selective serotonin reuptake inhibitor (SSRI) drugs
- Target: All drugs targeting Serotonin transporter (SERT)
- Manufacturer: Tri-Service General Hospital — full pipeline
- Therapeutic area: All drugs in Psychiatry / Neurology
- Indication: Drugs for Major depressive disorder
- Indication: Drugs for Obsessive-compulsive disorder
- Indication: Drugs for Panic disorder
- Also known as: Zoloft
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing